Allogene Therapeutics to restructure, deprioritize PhII CAR-T trials in clinical pivot

Allogene Therapeutics is switching up clinical plans for its off-the-shelf CAR-T therapies. In a bid to leapfrog more established rivals, the South San Francisco biotech will deprioritize two current Phase II trials of its lead candidate — its most advanced — and launch a new late-stage study with a much…
Click here to view original post